Dr Peter Szlosarek at the 18th IASLC World Conference on Lung Cancer

Reza Roozitalab Posted in Conferences, BCI on the Road 17 October 2017

ADI-PEG20 with Immune Checkpoint Blockade for Malignant Mesothelioma

Dr Peter Szlosarek, chief and principal investigator of several clinical studies here at the Barts Cancer Centre, will this Wednesday 18th October present exciting new data at the IASLC's (International Association for the Study of Lung Cancer) 18th World Conference on Lung Cancer, Yokohama, Japan.

Highlighting plans for future clinical studies, his talk, “Pegylated Arginine Deiminase Potentiates PD-1/PDL-1 Immune Checkpoint Blockade in Malignant Mesothelioma” will focus on the synergism between the arginine-lowering agent (AID-PEG20, Polaris Pharma) and PD1/PD-L1 axis immune checkpoint blockade in ASS1 negative tumours.

These new developments follow on from the success of the first-ever randomised trial of ADI-PEG20 in mesothelioma (ADAM) that reported an improvement in progression free survival (Szlosarek et al, Jama Onc 2017).

Leave a comment

You are commenting as guest. Optional login below.

This site uses cookies in order to function properly. By continuing to browse, you agree that we can save them on your device. Privacy Policy.